Multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of LJPC-501 in pediatric patients> 2 to 17 years of age with catecholamine-resistant hypotension associated with distributive shock.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: LA JOLLA PHARMACEUTICAL COMPANY
- Phase: II
- Execution start: 04/12/2018
- End of execution: 30/05/2021
- PI: ESTHER OCETE HITA